Brief: Supernus Announces FDA Approval Of Qelbree For The Treatment Of ADHD In Adults

Supernus Pharmaceuticals

30/04/2022 01:05

April 29 (Reuters) - Supernus Pharmaceuticals Inc  SUPN.O :
    * SUPERNUS ANNOUNCES FDA APPROVAL OF QELBREE® FOR THE
TREATMENT OF
ADHD IN ADULTS
    * SAYS FDA HAS NOW APPROVED QELBREE FOR TREATMENT OF ADHD IN
CHILDREN (STARTING AT AGE 6), ADOLESCENTS AND ADULTS
    * SAYS AT A DAILY FLEXIBLE-DOSE BETWEEN 200MG TO 600MG,
PHASE III
TRIAL MET PRIMARY ENDPOINT
    * SAYS FIRST NOVEL, NONSTIMULANT OPTION FOR ADULTS WITH ADHD
IN 20
YEARS

Source text for Eikon:  ID:nGNX9STvyM 
Further company coverage:  SUPN.O 

 ((Reuters.Briefs@thomsonreuters.com;))